Annual report
4978.TEDINET S100YLVF
Period2025-04-01 → 2026-03-31
Filed2026-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.2bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥3.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥2.4bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | −¥860m | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | −¥130m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | −¥581m | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥45m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥40m | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥120m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥507m | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥587m | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥45m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥592m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥103m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥31m | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥305m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥575m | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥592m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥103m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥9.7bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥9.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥9.1bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.4bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.1bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥806m | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥686m | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.8bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.0bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.3bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥7.6bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥7.3bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.8bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.6bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.6bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥384m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥11m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥141m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥246m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥58m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥796m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥404m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥680m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥544m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥483m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-6.25 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.11 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.37 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.62 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.57 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥93.09 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥94.89 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥93.41 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥89.01 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥88.11 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 91.7% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.8% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 1.2% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 101 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 99 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 96 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 92 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 98 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥624m | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥960m | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥941m | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.6bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.3bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | −¥609m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | −¥401m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | −¥331m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥285m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥62m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥112m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥382m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥339m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥304m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | −¥341m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | −¥306m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥205m | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥297m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥541m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥9.2bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥9.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥8.8bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥8.4bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥8.2bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥462m | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥368m | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥8.7bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.4bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥7.9bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.5bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.3bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-3.6 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.29 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-2.4 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.52 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.13 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥91.6 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥91.29 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥94.05 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥92.42 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥91.73 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 95.0% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.9% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.3% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.8% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.1% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 95,147,891 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 94,802,891 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 89,013,591 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,141,191 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 82,270,891 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 30 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 28 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 26 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 28 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 31 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 50
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥7m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥4m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥8.7bn |
| Reconciling Itemsreconciling | segment ordinary income | 2025-04-01 → 2026-03-31 | −¥634m |
| Medical Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥55m |
| Medical Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥46m |
| Medical Businessreportable segment | employees | at 2026-03-31 | 7 pure |
| Medical Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥281m |
| Medical Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥281m |
| Medical Businessreportable segment | segment assets | at 2026-03-31 | ¥282m |
| Medical Businessreportable segment | segment ordinary income | 2025-04-01 → 2026-03-31 | −¥44m |
| Research Support Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥37m |
| Research Support Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥22m |
| Research Support Businessreportable segment | employees | at 2026-03-31 | 70 pure |
| Research Support Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.0bn |
| Research Support Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.0bn |
| Research Support Businessreportable segment | segment assets | at 2026-03-31 | ¥632m |
| Research Support Businessreportable segment | segment ordinary income | 2025-04-01 → 2026-03-31 | ¥97m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥92m |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥69m |
| —segment total | employees | at 2026-03-31 | 77 pure |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥2.2bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥2.2bn |
| —segment total | segment assets | at 2026-03-31 | ¥914m |
| —segment total | segment ordinary income | 2025-04-01 → 2026-03-31 | ¥53m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥3m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥8.7bn |
| Reconciling Itemsreconciling | segment ordinary income | 2024-04-01 → 2025-03-31 | −¥735m |
| Medical Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥76m |
| Medical Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥25m |
| Medical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥564m |
| Medical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥564m |
| Medical Businessreportable segment | segment assets | at 2025-03-31 | ¥363m |
| Medical Businessreportable segment | segment ordinary income | 2024-04-01 → 2025-03-31 | ¥159m |
| Research Support Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥16m |
| Research Support Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥20m |
| Research Support Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.4bn |
| Research Support Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.4bn |
| Research Support Businessreportable segment | segment assets | at 2025-03-31 | ¥646m |
| Research Support Businessreportable segment | segment ordinary income | 2024-04-01 → 2025-03-31 | ¥621m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥91m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥45m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥3.0bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥3.0bn |
| —segment total | segment assets | at 2025-03-31 | ¥1.0bn |
| —segment total | segment ordinary income | 2024-04-01 → 2025-03-31 | ¥780m |
| Medical Businessreportable segment | employees | at 2026-03-31 | 7 pure |
| Research Support Businessreportable segment | employees | at 2026-03-31 | 16 pure |
| —segment total | employees | at 2026-03-31 | 23 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,391
| Item | Context | Value | Unit |
|---|---|---|---|
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0119 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.9016 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 1158950 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.0121 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 1000000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0105 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 832400 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0087 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 828600 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0087 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 728900 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0076 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 567600 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0059 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 500000 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0052 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 470800 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0049 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 455000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0047 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 453900 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0047 | |
| Number of shares held | CurrentYearInstant | 6996150 | |
| Shareholding ratio | CurrentYearInstant | 0.0736 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 117200 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 94979600 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 949796 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 51091 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 95147891 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 949796 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 117200 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 117200 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0012 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 117200 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 117200 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0012 | |
| Number of male directors and other officers | FilingDateInstant | 6 | |
| Number of female directors and other officers | FilingDateInstant | 0 | |
| Ratio of female directors and other officers | FilingDateInstant | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E27585-000YokoyamaChikafumiMember | 1158950 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E27585-000UsuiDaisukeMember | 315000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E27585-000YamakawaYoshiyukiMember | 50000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E27585-000NobuhisaYamazakiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E27585-000KushidaTakanoriMember | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |